中国药物警戒 ›› 2018, Vol. 15 ›› Issue (12): 713-720.

• 法规与管理研究 • 上一篇    下一篇

欧盟疫苗上市后安全监测体系研究

郗昊, 王翀*   

  1. 中国食品药品检定研究院技术监督中心,北京 102629
  • 收稿日期:2019-01-18 修回日期:2019-01-18 出版日期:2018-12-20 发布日期:2019-01-18
  • 通讯作者: 王翀,男,副主任药师,药品安全与国家药品抽检。E-mail:chongw99@foxmail.com。
  • 作者简介:郗昊,男,硕士,研究实习员,肿瘤学。

Research on Post-marketing Surveillance System of Vaccine in European Union

XI Hao, WANG Chong*   

  1. National Institute of Food and Drug Control, Technology Supervision Center, Beijing 102629, China
  • Received:2019-01-18 Revised:2019-01-18 Online:2018-12-20 Published:2019-01-18

PDF (PC)

874

摘要： 目的 通过介绍欧盟疫苗上市后安全监测体系,为我国疫苗上市后监管提供参考。方法 采用文献分析的方法,围绕疫苗上市后监测体系,搜集有关法律法规文献。结果 通过法律框架,欧盟提出了疫苗安全监测的特殊要求,以统一的数据库为基础,采用风险管理系统、定期安全性更新报告、设置重点监测名单等措施识别潜在不良反应信号,并通过注册后安全性研究对疫苗安全进行再评价。结论 欧盟建立了统一、长期监测体系和完善的药品安全沟通机制,将风险控制理念贯穿始终,这对我国有一定的借鉴意义。

关键词: 疫苗, 上市后监测体系, 参考

Abstract: Objective To offer reference for China, Post-marketing Surveillance System of Vaccine in European Union was introduced. Methods Literatures, regulations and laws relating to post-marketing surveillance system of vaccine were collected. Results Specific requirements were proposed by European Union through legal framework. Risk management system, periodic safety update report and additional monitoring list were utilized to recognize potential adverse events signal. Reevaluation of vaccine was proceeded by post-authorization safety studies. Conclusion European Union has established unified long-term monitoring system, completed drug safety communication mechanism and put the idea of risk control all through the process of surveillance.

Key words: vaccine, post-marketing surveillance system, reference

中图分类号: